MoonLake Immunotherapeutics Proposes $150M Public Offering to Fund Sonelokimab Development
MLTX has more than doubled off its 52-week low of $5.95 on elevated volume (3.3× avg).
Summary
MoonLake Immunotherapeutics announced a proposed public offering of $150 million in Class A ordinary shares, with an option for underwriters to purchase an additional $22.5 million. This significant capital raise, representing over 9% of the company's market cap, follows highly positive Week 52 Phase 3 clinical trial results for sonelokimab announced earlier today. The proceeds are intended to fund the research, development, and commercialization activities of sonelokimab, which is targeting a Q3 2026 BLA submission after a positive FDA meeting in May. While dilutive, this offering provides crucial capital for the company's lead asset as it moves towards market.
At the time of this announcement, MLTX was trading at $20.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.